Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Ophthalmic BioPharmaceutical

Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?

  • News

Executive Summary

There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.

You may also be interested in...



Oxurion Pins Hopes On THR-149 After THR-687 Flops In DME

THR-687’s failure in Phase II marks the second drug to flunk in the disease after a Phase IIa study of THR-317 showed disappointing results in 2019, but THR-149 has shown some encouraging data.

Kodiak’s KSI-301 Has Narrower Path Forward After Phase II/III Failure In Wet AMD

Monthly dosing remains a possibility in wet age-related macular degeneration, though diabetic macular edema and retinal vein occlusion look more promising.

Roche Veteran Launches Biotech Aiming To Disrupt Eye Drug Market

Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.

Table

View full table

Related Content

Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Biosimilars Ophthalmic BioPharmaceutical
Latest Headlines

China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public

Quick Listen: Scrip's Five Must-Know Things

AbbVie Exits CAR-T Cell Therapy Development Partnership With Caribou

Blueprint’s Evolution On Its Path To Financial Sustainability

See All
UsernamePublicRestriction

Register

SC145893

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By